News Releases
by Category
R&D
Nov. 22, 2022 (PDF/193KB) R&D
GARDP and Sumitomo Pharma announce partnership in search for new antibiotics
Sep. 29, 2022 (PDF/160KB) R&D
Joint Research between The Kitasato Institute and Sumitomo Pharma: Drug Combination of Meropenem and KSP-1007 for Treatment of Carbapenem-Resistant Bacteria Infections Designated as Qualified Infectious Disease Product (QIDP)/Fast Track
Jun. 03, 2022 (PDF/91KB) R&D
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE
May 09, 2022 (PDF/251KB) R&D
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE for the Management of Moderate to Severe Pain Associated With Endometriosis
Apr. 12, 2022 (PDF/255KB) R&D
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE for the Management of Moderate to Severe Pain Associated with Endometriosis
Mar. 31, 2022 (PDF/410KB) R&D
National Cancer Center Japan, Shonai Regional Industry Promotion Center and Sumitomo Dainippon Pharma Announce Start of Phase 1/2 Study on New Drug Candidate Compound in Acute Myeloid Leukemia
Feb. 28, 2022 (PDF/45KB) R&D
Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX (relugolix) for the Treatment of Advanced Prostate Cancer
Jan. 13, 2022 (PDF/173KB) R&D
Kitasato Institute and Sumitomo Dainippon Pharma Start Phase 1 Study on New Drug Candidate Compound Discovered in Joint Research as Treatment for Carbapenem-resistant Bacterial Infections
Dec. 15, 2021 (PDF/119KB) R&D
Sumitomo Dainippon Pharma Announces Phase 3 Study of Investigational Cancer Vaccine DSP-7888 in Patients with Glioblastoma Terminates
Sep. 14, 2021 R&D
Posted Video of Frontier Business Meeting - FBO Showcase - [Webcast]
Sep. 10, 2021 (PDF/109KB) R&D
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE for the Management of Moderate to Severe Pain Associated With Endometriosis
Sep. 08, 2021 (PDF/18,450KB) R&D
Posted Presentation Material (Frontier Business Meeting - FBO Showcase -)
Sep. 03, 2021 (PDF/152KB) R&D
Sumitomo Dainippon Pharma and Pixie Dust Technologies Sign Joint R&D Agreement on Communication Support Smart Glasses for Hard of Hearing People
May 24, 2021 (PDF/40KB) R&D
Myovant Sciences Receives Positive CHMP Opinion for RYEQO (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids
Apr. 28, 2021 (PDF/80KB) R&D
ENZYVANT Resubmits Biologics Licensing Application (BLA) to FDA for RVT-802 for Pediatric Congenital Athymia
Mar. 31, 2021 (PDF/194KB) R&D
The GHIT Fund Awards Grant for the Development of a New Malaria Pre-erythrocytic Vaccine
Mar. 30, 2021 (PDF/38KB) R&D
Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate Cancer
Mar. 29, 2021 R&D
Posted Video of Sumitovant Meeting [Webcast]
Mar. 23, 2021 (PDF/6,694KB) R&D
Posted Presentation Material (Sumitovant Meeting)
Feb. 18, 2021 (PDF/52KB) R&D
Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Feb. 09, 2021 (PDF/126KB) R&D
Sumitomo Dainippon Pharma Announces Topline Results of Phase 3 Study on Investigational Anti-Cancer Agent Napabucasin Fails to Reach Primary Endpoints in Patients with Colorectal Cancer
Jan. 27, 2021 (PDF/52KB) R&D
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Nov. 25, 2020 (PDF/30KB) R&D
Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint
Oct. 27, 2020 (PDF/223KB) R&D
Joint Research and Development Agreement with Drawbridge Health, Inc. on Innovative Blood Sampling Solution for Lifestyle Diseases
Sep. 30, 2020 (PDF/98KB) R&D
Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate Cancer
Aug. 18, 2020 (PDF/46KB) R&D
Myovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids
Aug. 05, 2020 (PDF/355KB) R&D
Sumitomo Dainippon Pharma, Sompo Japan, and Aikomi Announce Collaboration on R&D and Commercialization of Digital Devices for Dementia and Nursing Care
Aug. 03, 2020 (PDF/120KB) R&D
Save Medical and Sumitomo Dainippon Pharma Announce Signing of Joint Development Agreement for Mobile App for Management of Type 2 Diabetes and Commencement of Clinical Study
Jul. 30, 2020 (PDF/101KB) R&D
Sumitomo Dainippon Pharma Submits New Drug Application for Approval of Manufacturing and Marketing for Imeglimin Hydrochloride for the Treatment of Type 2 Diabetes in Japan
Jul. 07, 2020 (PDF/224KB) R&D
Sunovion Announces Topline Results from Global Phase 2 Study of SEP-4199 in Patients with Bipolar I Depression
Jun. 24, 2020 (PDF/50KB) R&D
Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Jun. 23, 2020 (PDF/50KB) R&D
Myovant Sciences Announces Priority Review and FDA Acceptance of New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer
Jun. 02, 2020 (PDF/47KB) R&D
Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
Jun. 01, 2020 (PDF/104KB) R&D
Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine
Apr. 24, 2020 (PDF/301KB) R&D
Sumitomo Dainippon Pharma and National Institutes of Biomedical Innovation, Health and Nutrition Conclude Joint Research Agreement for Universal Influenza Vaccine
Apr. 24, 2020 (PDF/1,143KB) R&D
Supplementary Material (Sumitomo Dainippon Pharma and National Institutes of Biomedical Innovation, Health and Nutrition Conclude Joint Research Agreement for Universal Influenza Vaccine)
Apr. 23, 2020 (PDF/50KB) R&D
Myovant Sciences Announces Positive Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis and from Ovulation Inhibition Study
Apr. 22, 2020 (PDF/50KB) R&D
Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily, Oral Relugolix for the Treatment of Men with Advanced Prostate Cancer
Apr. 16, 2020 (PDF/287KB) R&D
New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion's SEP-363856 for the Treatment of Schizophrenia
Apr. 03, 2020 (PDF/262KB) R&D
The GHIT Fund Awards Grant for the Development of a New Malaria Transmission-Blocking Vaccine by Ehime University and Sumitomo Dainippon Pharma
Mar. 10, 2020 (PDF/47KB) R&D
Myovant Sciences Submits Marketing Authorization Application to the European Medicines Agency for Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
Mar. 09, 2020 R&D
Posted Video of R&D Meeting [Webcast]
Mar. 06, 2020 (PDF/187KB) R&D
Urovant Sciences Announces U.S. FDA Acceptance of New Drug Application for Vibegron for the Treatment of Overactive Bladder
Mar. 03, 2020 (PDF/10,286KB) R&D
Posted Presentation Material (R&D Meeting)
Jan. 30, 2020 (PDF/253KB) R&D
Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Study
Jan. 06, 2020 (PDF/20KB) R&D
Urovant Sciences Announces Submission of New Drug Application for Vibegron for the Treatment of Overactive Bladder
Dec. 23, 2019 (PDF/488KB) R&D
Sunovion Announces FDA Filing Acceptance of Resubmitted New Drug Application for Apomorphine Sublingual Film
Dec. 20, 2019 (PDF/244KB) R&D
Poxel and Sumitomo Dainippon Pharma Announce Positive Topline Phase 3 Results from TIMES 2 Trial of Imeglimin for the Treatment of Type 2 Diabetes in Japan and Successful Completion of the Pivotal TIMES Clinical Development Program
Dec. 04, 2019 (PDF/126KB) R&D
Boston Biomedical, Inc. Enters into an Alliance in Oncology Research with Columbia University, Harvard University and The Wistar Institute
Nov. 25, 2019 (PDF/641KB) R&D
Sunovion Resubmits New Drug Application for Apomorphine Sublingual Film
Nov. 14, 2019 (PDF/425KB) R&D
iPS Cell Research Discovers Common Pathologies in Psychiatric Disorders Elucidation of the Pathogenesis of Bipolar Disorder and Schizophrenia May Find Application in Therapeutic Drug Development
Jul. 31, 2019 (PDF/123KB) R&D
Sumitomo Dainippon Pharma Submits New Drug Application for Approval of Manufacturing and Marketing for Lurasidone in Japan for the Treatment of Schizophrenia and Bipolar Depression
Jul. 31, 2019 (PDF/173KB) R&D
Sunovion Announces Acceptance by the U.S. FDA of the New Drug Application for Dasotraline for the Treatment of Adults with Moderate-to-Severe Binge Eating Disorder
Jul. 22, 2019 (PDF/240KB) R&D
Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase 3 Clinical Study of LONASEN, an Atypical Antipsychotic Agent, in the Treatment of Adolescent Patients with Schizophrenia in Japan
Jul. 02, 2019 (PDF/125KB) R&D
Sumitomo Dainippon Pharma Announces Discontinuation of Phase 3 CanStem111P Study of Investigational Anti-Cancer Agent Napabucasin in Patients with Pancreatic Cancer Following Interim Analysis
Jun. 25, 2019 (PDF/169KB) R&D
Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 3) in Japan for the Treatment of Type 2 Diabetes
Jun. 13, 2019 (PDF/82KB) R&D
Sumitomo Dainippon Pharma announces Changes to Agreement on Joint Development of Treatments for Eye Diseases Using iPS Cell-derived Retinal Pigment Epithelial Cells in Japan
Jun. 07, 2019 (PDF/127KB) R&D
Sumitomo Dainippon Pharma Announces Recommendation to Continue Phase 3 CanStem303C Study of Investigational Anti-Cancer Agent Napabucasin in Patients with Colorectal Cancer Following Interim Analysis
May 10, 2019 (PDF/574KB) R&D
Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia
Apr. 09, 2019 (PDF/167KB) R&D
Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 1) in Japan for the Treatment of Type 2 Diabetes
Apr. 09, 2019 (PDF/101KB) R&D
GHIT Fund Awards Grant for Continuing Development of Malaria Vaccine Discovered by Ehime University and Sumitomo Dainippon Pharma
Apr. 05, 2019 (PDF/143KB) R&D
Five Partners Commence Joint R&D on Renal Regenerative Medicine
Apr. 02, 2019 (PDF/81KB) R&D
Sumitomo Dainippon Pharma Submits an Application of RETHIO for an Additional Indication of Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma
Feb. 08, 2019 (PDF/140KB) R&D
Sumitomo Dainippon Pharma and Aikomi Conclude Joint Research Agreement on Medical Devices to Relieve Behavioral and Psychological Symptoms of Dementia
Jan. 31, 2019 (PDF/161KB) R&D
Sunovion Receives Complete Response Letter from FDA for Apomorphine Sublingual Film (APL-130277)
Jan. 29, 2019 (PDF/302KB) R&D
SanBio and Sumitomo Dainippon Pharma Announce Topline Results from a Phase 2b Study in the U.S. Evaluating SB623, a Regenerative Cell Medicine for the Treatment of Patients with Chronic Stroke
Jan. 10, 2019 (PDF/86KB) R&D
Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase III Clinical Study (JEWEL Study) of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Schizophrenia
Dec. 21, 2018 (PDF/127KB) R&D
Kyoto University's Center for iPS Cell Research and Application, Sumitomo Chemical, and Sumitomo Dainippon Pharma Commence Joint Research on Producing Higher-Quality iPS Cells for Clinical Use
Nov. 02, 2018 (PDF/116KB) R&D
Sumitomo Dainippon Pharma announces the Clinical Data of Investigational Anti-Cancer Agent Alvocidib will be presented at ASH 2018
Oct. 17, 2018 (PDF/118KB) R&D
Sumitomo Dainippon Pharma to Invest in and Start Joint Research and Development with MELTIN
Sep. 10, 2018 (PDF/210KB) R&D
Results of Phase 3 Studies Evaluating Patch Formulation of Atypical Antipsychotic LONASEN Presented at Congress
Sep. 01, 2018 (PDF/228KB) R&D
FDA Issues a Complete Response Letter for New Drug Application for Dasotraline for the Treatment of ADHD
Jul. 31, 2018 (PDF/107KB) R&D
New Drug Application in Japan for Transdermal Patch Formulation of Atypical Antipsychotic LONASEN
Jul. 30, 2018 (PDF/84KB) R&D
Kyoto University Hospital and the Center for iPS Cell Research and Application (CiRA) to begin Physician-initiated Clinical Trials for Parkinson's Disease that Transplants Dopamine progenitor cells generated from Induced Pluripotent Stem (iPS) Cells
Jul. 26, 2018 (PDF/323KB) R&D
Sunovion Announces Positive Top-Line Results from Pivotal Study Evaluating Dasotraline in Adults with Binge Eating Disorder
Jul. 04, 2018 (PDF/86KB) R&D
Sumitomo Dainippon Pharma Submits New Drug Application for Thiotepa in Japan for Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors
Jun. 25, 2018 (PDF/620KB) R&D
Sunovion Presents Data from Pivotal Phase 3 Study of Apomorphine Sublingual Film (APL-130277) at the 2nd Pan American Parkinson's Disease and Movement Disorders Congress
Jun. 13, 2018 (PDF/438KB) R&D
Sunovion Announces FDA Acceptance of New Drug Application for Apomorphine Sublingual Film (APL-130277)
May 18, 2018 (PDF/119KB) R&D
Sumitomo Dainippon Pharma announces the Clinical Data of Investigational Anti-Cancer Agent Alvocidib will be presented at EHA2018
May 17, 2018 (PDF/97KB) R&D
Sumitomo Dainippon Pharma announces the Clinical Data will be presented at ASCO 2018
Apr. 25, 2018 (PDF/108KB) R&D
Sumitomo Dainippon Pharma Announces Joint Research Agreement with MMV for Identification of Antimalarial Candidate Compounds
Apr. 02, 2018 (PDF/387KB) R&D
Sunovion Submits New Drug Application to the FDA for Apomorphine Sublingual Film (APL-130277) for the Treatment of OFF Episodes Associated with Parkinson's Disease
Mar. 27, 2018 (PDF/118KB) R&D
Carna Biosciences and Sumitomo Dainippon Pharma Sign Agreement on Joint Research, Development, and Commercialization of Kinase Inhibitors
Feb. 14, 2018 (PDF/287KB) R&D
Sumitomo Dainippon Pharma and Nitto Announce Positive Topline Results from Phase 3 Study Evaluating Transdermal Patch Formulation of Atypical Antipsychotic LONASEN
Jan. 30, 2018 (PDF/355KB) R&D
Sunovion Announces Positive Topline Results from Pivotal Study of Apomorphine Sublingual Film (APL-130277) in Patients with Parkinson's Disease
Dec. 27, 2017 (PDF/143KB) R&D
Poxel and Sumitomo Dainippon Pharma Announce Initiation of Phase 3 Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan
Nov. 13, 2017 (PDF/206KB) R&D
Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD
Oct. 24, 2017 (PDF/243KB) R&D
Kitasato Institute and Sumitomo Dainippon Pharma Sign a Joint Drug Discovery Research Agreement for Infections Caused by Bacteria with Antimicrobial Resistance (AMR)
Sep. 01, 2017 (PDF/247KB) R&D
Sunovion Submits New Drug Application for Dasotraline to the FDA for the Treatment of Patients with ADHD
Aug. 30, 2017 (PDF/105KB) R&D
Sumitomo Dainippon Pharma Submits an Application in Japan for TRERIEF, a therapeutic agent for Parkinson's disease, for an Additional Indication of Parkinsonism in Dementia with Lewy Bodies
Jul. 03, 2017 (PDF/301KB) R&D
Sunovion Announces FDA Acceptance for Review of New Drug Application Resubmission for SUN-101/eFlow (glycopyrrolate) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Jun. 26, 2017 (PDF/75KB) R&D
Sumitomo Dainippon Pharma Announces Unblinding of Phase 3 Study of Napabucasin, a cancer stemness inhibitor, in Patients with Gastric/GEJ Cancer
Jun. 09, 2017 (PDF/131KB) R&D
Sumitomo Dainippon Pharma Announces Topline Results from a Phase 3 Study of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Bipolar l Depression
May 29, 2017 (PDF/348KB) R&D
Sunovion Receives Complete Response Letter from FDA for SUN-101/eFlow (glycopyrrolate) New Drug Application for Chronic Obstructive Pulmonary Disease (COPD)
May 18, 2017 (PDF/131KB) R&D
Sumitomo Dainippon Pharma announces the Clinical Data will be presented at ASCO 2017
Apr. 12, 2017 (PDF/81KB) R&D
Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase 3 Study of Novel Drug Candidate Dasotraline Being Evaluated in the Treatment of Children with Attention Deficit Hyperactivity Disorder (ADHD)
Apr. 06, 2017 (PDF/53KB) R&D
Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase 3 Study of TRERIEF, a therapeutic agent for Parkinson's disease, in the Treatment of Patients with Parkinsonism in Dementia with Lewy Bodies (DLB)
Feb. 28, 2017 (PDF/57KB) R&D
Sumitomo Dainippon Pharma announces Allogeneic iPS cell-derived Dopaminergic Neural Progenitor Cells Designated a "SAKIGAKE" Product by Japan's Ministry of Health, Labour and Welfare
Jan. 23, 2017 (PDF/161KB) R&D
Sumitomo Dainippon Pharma Announces Clinical Data of Investigational Cancer Stemness Inhibitor Napabucasin were presented at 2017 ASCO GI Symposium
Jan. 14, 2017 (PDF/184KB) R&D
Sunovion Announces Pivotal Study Results for Novel Drug Candidate Dasotraline Demonstrating Significantly Improved Attention Deficit Hyperactivity Disorder Symptoms in Children Compared to Placebo
Jan. 13, 2017 (PDF/240KB) R&D
Sunovion Announces Top-line Results from Studies Evaluating Dasotraline in Adults with Binge Eating Disorder and Attention Deficit Hyperactivity Disorder
Nov. 04, 2016 (PDF/95KB) R&D
Sumitomo Dainippon Pharma announces the data of an investigational WT1 cancer peptide vaccine, DSP-7888 will be presented at the ASH 2016
Oct. 13, 2016 (PDF/322KB) R&D
Sunovion Announces FDA Filing Acceptance of New Drug Application for SUN-101/eFlow for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)
Oct. 06, 2016 (PDF/146KB) R&D
Sumitomo Dainippon Pharma announces the final data analysis of a global phase 3 study of an investigational anti-cancer drug Napabucasin (CO.23 study) will be presented at the ESMO 2016 Congress
Sep. 20, 2016 (PDF/188KB) R&D
Sunovion Announces Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Children with ADHD
Jul. 29, 2016 (PDF/316KB) R&D
Sunovion Submits New Drug Application for SUN-101/eFlow to the FDA for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)
Jul. 26, 2016 (PDF/76KB) R&D
Sysmex, Healios and Sumitomo Dainippon Pharma Begin Joint R&D Related to Pre-Transplant Immune Reaction Testing Method for Retinal Pigment Epithelial Cells (RPE Cells) Derived from Allogeneic iPS Cells
May 19, 2016 (PDF/58KB) R&D
Sumitomo Dainippon Pharma announces Clinical Data of Investigational anti-cancer drugs Napabucasin and Amcasertib in Multiple Cancer Types at ASCO 2016
Apr. 27, 2016 (PDF/316KB) R&D
Sunovion Pharmaceuticals Inc. Announces Positive Results from Two Phase 3 Clinical Studies Evaluating SUN-101/eFlow (glycopyrrolate) in People with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Apr. 11, 2016 (PDF/115KB) R&D
Kyoto University and Sumitomo Dainippon Pharma Launch Second Stage of Joint Research Project for Innovative Oncology Therapeutics (DSK Project)
Jan. 25, 2016 (PDF/57KB) R&D
Boston Biomedical’s Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO 2016 Gastrointestinal Cancers Symposium
Jan. 25, 2016 (PDF/229KB) R&D
Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline
Jul. 24, 2015 (PDF/223KB) R&D
Sumitomo Dainippon Pharma,CiRA and Hitachi Start Joint Research on Development of Key Evaluation Technologies: Evaluation for Industrialization in the Field of Regenerative Medicine -Toward Application of Human iPS Cell for Parkinson's Disease Treatment-
Jun. 17, 2015 (PDF/89KB) R&D
JCR and Sumitomo Dainippon Pharma Conclude a Feasibility Study Agreement on Application of the Blood-Brain Barrier Penetration Technology in Psychiatry and Neurology Area
Jun. 01, 2015 (PDF/329KB) R&D
Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types
May 19, 2015 (PDF/195KB) R&D
Sunovion Pharmaceuticals Inc. Announces Positive Results for Latuda (lurasidone HCl) in First Placebo-Controlled Trial of Patients with Major Depressive Disorder with Mixed (Subsyndromal Hypomanic) Features
May 13, 2015 (PDF/353KB) R&D
Boston Biomedical to Highlight Data Examining Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types at ASCO 2015
Apr. 24, 2015 (PDF/179KB) R&D
Sumitomo Dainippon Pharma Makes a Follow-up Announcement on the Preliminary Findings from a Phase III Clinical Study (PASTEL Study) of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Schizophrenia
Feb. 26, 2015 (PDF/326KB) R&D
Sunovion Pharmaceuticals Inc. Announces Initiation of Phase 3 Clinical Trial Program for SUN-101/eFlow® (Glycopyrrolate) in Moderate-to-Very SevereChronic Obstructive Pulmonary Disease (COPD)
Jan. 07, 2015 (PDF/196KB) R&D
Sunovion Pharmaceuticals Inc. Announces FDA Acceptance for Review of Supplemental New Drug Application for the Use of Aptiom (eslicarbazepine acetate) as Monotherapy Treatment for Partial Onset Seizures
Dec. 25, 2014 (PDF/176KB) R&D
Sumitomo Dainippon Pharma Announces Preliminary Findings from a Phase III Clinical Study (PASTEL Study) of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Schizophrenia
Dec. 11, 2014 (PDF/171KB) R&D
Investigational Drug Dasotraline Significantly Improved Symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in a Placebo-Controlled Study in Adults
Jun. 06, 2014 (PDF/156KB) R&D
Dainippon Sumitomo Pharma announces clinical data of anti-cancer drugs BBI608 and BBI503 were presented at the 2014 ASCO Annual Meeting
May 23, 2014 (PDF/115KB) R&D
Dainippon Sumitomo Pharma announces closure to furtherpatient accrual on its CO.23 study: a phase III global colorectal carcinoma monotherapy trial
May 15, 2014 (PDF/169KB) R&D
Dainippon Sumitomo Pharma announces clinical data of anti-cancer drugs BBI608 and BBI503 will be presented at the 2014 ASCO Annual Meeting
Jan. 27, 2014 (PDF/114KB) R&D
Global Collaboration Forms to Advance Japanese TB Vaccine Technology
Jan. 27, 2014 (PDF/147KB) R&D
Dainippon Sumitomo Pharma and Takeda Receive Positive CHMP Opinion for Lurasidone - a New Atypical Antipsychotic Medication for Adults with Schizophrenia
Dec. 25, 2013 (PDF/94KB) R&D
Dainippon Sumitomo Pharma submits an application for partial change of the approved indication to "Type 2 Diabetes" for SUREPOST, a rapid-acting insulin secretagogue
Dec. 09, 2013 (PDF/97KB) R&D
Sunovion Pharmaceuticals Inc. Presents Positive Results From Two Phase 3 Studies of Once-Daily Aptiom(eslicarbazepine acetate) as Monotherapy Treatment for Partial-Onset Seizures
Dec. 02, 2013 (PDF/94KB) R&D
Healios and Dainippon Sumitomo Pharma form an alliancein regenerative medicine and cell therapy--- Joint development of the world’s first regenerative medicine/cell therapy business based on iPS cell technology ---
Oct. 28, 2013 (PDF/150KB) R&D
Application for Marketing Approval Submitted in Taiwan for Atypical Antipsychotic Agent Lurasidone
Sep. 27, 2013 (PDF/32KB) R&D
Dainippon Sumitomo Pharma submits an application for an atypical antipsychotic blonanserin (Brand name in Japan: LONASEN) in China
Sep. 18, 2013 (PDF/29KB) R&D
Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Acceptance for Review of the New Drug Submission of eslicarbazepine acetate as a Once-Daily Adjunctive Therapy for PartialonsetSeizures in Adults with Epilepsy
Sep. 17, 2013 (PDF/81KB) R&D
Sunovion Reports Eslicarbazepine Acetate Meets Primary Endpoint in Two Phase 3 Monotherapy Studies for Partial-onset Seizures in Adults with Epilepsy
Aug. 06, 2013 (PDF/65KB) R&D
Application Submission for Approval for the Stability-Improved Formulation of Limaprost, an Oral Prostaglandin E1 Analogue in Japan
Jun. 04, 2013 (PDF/110KB) R&D
Dainippon Sumitomo Pharma announces BBI608 Phase 1/2 Clinical Study Data (Dose-Escalation Study) was presented at the 2013 ASCO Annual Meeting
May 16, 2013 (PDF/65KB) R&D
Dainippon Sumitomo Pharma announces BBI608 Clinical Study Data to be presented at the 2013 ASCO Annual Meeting
May 09, 2013 (PDF/41KB) R&D
Dainippon Sumitomo Pharma announces BBI608 Phase 1 Clinical Study Data to be presented at the 2013 ASCO Annual Meeting
Apr. 15, 2013 (PDF/34KB) R&D
Dainippon Sumitomo Pharma Submits Marketing Authorization Application in Australia for Atypical Antipsychotic Agent Lurasidone
Apr. 08, 2013 (PDF/23KB) R&D
Dainippon Sumitomo Pharma and Chugai Pharmaceutical Terminate Joint Development of Cancer Vaccine
Feb. 28, 2013 (PDF/138KB) R&D
Sunovion Announces FDA Acceptance for Review of New Drug Application Resubmission for STEDESA (eslicarbazepine acetate) as a Once-Daily Adjunctive Therapy for Partial-onset Seizures in Adults with Epilepsy
Jan. 25, 2013 (PDF/17KB) R&D
Discontinuation of Development for the Additional Indication of Carpal-Tunnel Syndrome, for Limaprost, an Oral Prostaglandin E1 Analogue
Jan. 22, 2013 (PDF/44KB) R&D
Dainippon Sumitomo Pharma files an application in Japan for a partial change in the approved dosage and administration of MEROPEN, a carbapenem antibiotic preparation, when used for the treatment of bacterial meningitis
Oct. 31, 2012 (PDF/108KB) R&D
Sunovion Pharmaceuticals Inc. Announces FDA Acceptance of Two Supplemental New Drug Applications for the Use of Latuda (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Depressive Episodes Associated with Bipolar I Disorder
Oct. 25, 2012 (PDF/124KB) R&D
DSP and Takeda Announce the Acceptance of the European Medicines Agency Submission of an Atypical Antipsychotic Agent Lurasidone
Sep. 07, 2012 (PDF/187KB) R&D
Sunovion Pharmaceuticals Files Two Supplemental New Drug Applications Seeking Approval for the use of Latuda (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Depressive Episodes Associated with Bipolar I Disorder
Sep. 05, 2012 (PDF/98KB) R&D
Dainippon Sumitomo Pharma submits an application for anticancer antibiotic amrubicin HCI (Brand name in Japan: CALSED) in China
Jul. 27, 2012 (PDF/84KB) R&D
Dainippon Sumitomo Pharma and Nitto Denko Joint Development Phase 2 studies start on the world's first transdermal patch formulation for schizophrenia treatment
May 07, 2012 (PDF/118KB) R&D
Dainippon Sumitomo Pharma Co. Reports that Latuda (lurasidone HCl) Met Primary and Key Secondary Endpoints in Two Phase III Trials in Bipolar I Depression (Updated version)
Apr. 24, 2012 (PDF/118KB) R&D
Dainippon Sumitomo Pharma Co. Reports that Latuda (lurasidone HCl) Met Primary and Key Secondary Endpoints in Two Phase III Trials in Bipolar I Depression
Apr. 17, 2012 (PDF/44KB) R&D
Dainippon Sumitomo Pharma submits an application for SUREPOST, a rapid-acting insulin secretagogue, for the additional indication of combination therapy with thiazolidinediones and with biguanides
Feb. 20, 2012 (PDF/85KB) R&D
Dainippon Sumitomo Pharma Submits Application Based on Public Knowledge for long-acting calcium antagonist AMLODIN tablets/OD tablets for the Additional Indication of "Hypertension in pediatric patients"
Dec. 05, 2011 (PDF/153KB) R&D
STEDESA™ clinical data presented at 2011 American Epilepsy Society Annual Meeting
Nov. 30, 2011 (PDF/43KB) R&D
Dainippon Sumitomo Pharma announces application for manufacturing and marketing approval for "DSP-8153", combination product of irbesartan and amlodipine besilate
Oct. 27, 2011 (PDF/102KB) R&D
LATUDA (lurasidone HCl) Shown to be Non-Inferior to SEROQUEL XR (quetiapine fumarate XR) in Risk for Relapse in a 12-Month, Double-Blind Extension Study of Adult Patients with Schizophrenia
Aug. 24, 2011 (PDF/35KB) R&D
Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Acceptance of Lurasidone New Drug Submission for Treatment of Schizophrenia
Jun. 07, 2011 (PDF/60KB) R&D
Collaborative Research on Apoptosis Inhibitor of Macrophages (AIM)
Jun. 07, 2011 (PDF/55KB) R&D
Sunovion Announces FDA Acceptance of New Drug Application for Ciclesonide HFA Nasal Aerosol
Jun. 01, 2011 (PDF/50KB) R&D
Announcement on Co-development and Co-marketing Agreement for Carpal-tunnel Syndrome, an Additional Indication of Limaprost, an Oral Prostaglandin E1 Analogue
May 11, 2011 (PDF/122KB) R&D
Results of a Phase II Clinical Trial for Ranirestat - Therapeutic Agent for Diabetic Complications
May 11, 2011 (PDF/120KB) R&D
Dainippon Sumitomo Pharma announces Pan-Asia study results for lurasidone, an atypical antipsychotic agent, in the treatment of schizophrenia
Apr. 25, 2011 (PDF/115KB) R&D
CiRA and DSP Research the Creation of a New Treatment for Rare Intractable Diseases
Mar. 15, 2011 (PDF/37KB) R&D
Laboratory for Malignancy Control Research
Jan. 25, 2011 (PDF/50KB) R&D
Completion of Long-Term Phase 3 Safety Trial for Latuda (lurasidone HCl)
Dec. 21, 2010 (PDF/20KB) R&D
Joint development of therapeutic cancer vaccine WT4869
Nov. 02, 2010 (PDF/48KB) R&D
LATUDA (lurasidone HCl) SIGNIFICANTLY REDUCED SYMPTOMS OF SCHIZOPHRENIA IN NEW CLINICAL STUDY
Jul. 01, 2010 (PDF/111KB) R&D
SEPRACOR REPORTS PRELIMINARY RESULTS FROM A SECOND PHASE III STUDY FOR OMNARIS HFA NASAL AEROSOL IN SEASONAL ALLERGIC RHINITIS
May 31, 2010 (PDF/45KB) R&D
Application for partial change of approval of the dosage and administration of MEROPEN, a carbapenem antibiotic preparation
May 06, 2010 (PDF/62KB) R&D
FDA PROVIDES COMPLETE RESPONSE TO SEPRACOR’S NEW DRUG APPLICATION FOR STEDESA
Mar. 11, 2010 (PDF/42KB) R&D
Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia
Jan. 28, 2010 (PDF/47KB) R&D
FDA extends PDUFA action date for STEDESA new drug application
Jan. 05, 2010 (PDF/70KB) R&D
Dainippon Sumitomo Pharma America Announces the NDA Submission of Lurasidone to the FDA for the Treatment of Schizophrenia
Aug. 26, 2009 (PDF/92KB) R&D
LURASIDONE DEMONSTRATED EFFICACY IN TREATING PATIENTS WITH SCHIZOPHRENIA IN PIVOTAL PHASE 3 STUDY
Jun. 03, 2009 (PDF/88KB) R&D
STUDY DEMONSTRATING LURASIDONE IS EFFECTIVE IN PATIENTS WITH SCHIZOPHRENIA PUBLISHED IN THE JOURNAL OF CLINICAL PSYCHIATRY
May 21, 2009 (PDF/106KB) R&D
DAINIPPON SUMITOMO PHARMA ANNOUNCES LURASIDONE PHASE III DATA IN PATIENTS WITH SCHIZOPHRENIA
Apr. 17, 2009 (PDF/36KB) R&D
Discontinuation of development of AC-3933, a therapeutic agent for dementia
Oct. 23, 2008 (PDF/42KB) R&D
Notice of establishment of Drug Discovery Consortium in neuropsychiatric area
May 08, 2008 (PDF/35KB) R&D
Novel Therapeutic Agent for Allergic Disorders Discovered in Collaboration with AstraZeneca Progresses to Clinical Development Stage
Apr. 17, 2008 (PDF/14KB) R&D
Discontinuation of Development for an Additional Indication of Cervical Spondylosis of Limaprost Alfadex, an Oral Prostaglandin E1 Derivative Preparation
Dec. 13, 2006 (PDF/60KB) R&D
Review of overseas development of Lurasidone (SM-13496), an atypical antipsychotic
Nov. 28, 2006 (PDF/106KB) R&D
Revising domestic development plan of AC-5216, an antianxiety/antidepressant agent